ValiRx plc
VAL.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | £758 | £1,026 | £4,133 | £6,037 |
| - Cash | £519 | £1,556 | £809 | £175 |
| + Debt | £7 | £12 | £17 | £22 |
| Enterprise Value | £246 | -£518 | £3,340 | £5,884 |
| Revenue | – | £50 | £0 | £10 |
| % Growth | – | – | -100% | – |
| Gross Profit | – | -£83 | -£134 | -£128 |
| % Margin | – | -166.8% | – | -1,331.5% |
| EBITDA | – | -£915 | -£918 | -£1,011 |
| % Margin | – | -1,837.5% | – | -10,533.7% |
| Net Income | – | -£945 | -£971 | -£1,002 |
| % Margin | – | -1,898.1% | – | -10,440.4% |
| EPS Diluted | – | -0.007 | -0.007 | -0.01 |
| % Growth | – | 4.1% | 24.5% | – |
| Operating Cash Flow | – | -£701 | -£884 | -£668 |
| Capital Expenditures | – | -£10 | -£28 | -£3 |
| Free Cash Flow | – | -£711 | -£912 | -£671 |